SK Capital Partners said Feb. 25 that it closed its latest fund on about $2.1 billion of capital. Fund V includes a separate overage pool that will allow SK to pursue larger transactions. Investors include public pension funds, insurance companies, fund-of-funds, endowments, sovereign wealth funds, foundations and family offices. Kirkland & Ellis LLP served as legal adviser while UBS served as placement agent to SK Capital.
SK Capital Partners Closes Fund V with Over $2 Billion in Total Capital
NEW YORK, NY – February 25, 2019 – SK Capital Partners, a private investment firm focused on the specialty materials, chemicals and pharmaceuticals sectors, announced the final close of SK Capital Partners Fund V with total committed capital of approximately $2.1 billion. Fund V includes a separate overage fund that will enable the firm to provide greater speed and certainty to sellers when it pursues larger transactions.
SK Capital Partners Fund V is the firm’s largest fund to date, eclipsing its $500 million fund raised in 2011 and its $1 billion predecessor fund raised in 2014. SK Capital currently has over $4 billion of assets under management.
SK received strong support from a diverse network of investors, including public pension funds, insurance companies, fund-of-funds, endowments, sovereign wealth funds, foundations and family offices.
“We are pleased by the tremendous demand for Fund V. Both the quality and diversity of our limited partners is indicative of their broad support for SK Capital’s disciplined strategy and strong team that incorporates both deep industry experience and diverse operating skill sets to deliver our targeted returns,” said Barry Siadat, Co-Founder and Managing Director of SK Capital Partners.
“We are grateful to our longtime limited partners for their continuing support and are delighted to welcome a number of new institutional investors to the SK Capital family,” said Jamshid Keynejad, Co-Founder and Managing Director of SK Capital Partners.
In October 2018, the firm made its initial investment from SK Capital Partners Fund V as part of its acquisition of SI Group.
Kirkland & Ellis LLP served as legal advisor and UBS served as placement agent to SK Capital.
About SK Capital
SK Capital is a private investment firm with a disciplined focus on the specialty materials, chemicals and pharmaceuticals sectors. The firm seeks to build strong and growing businesses that create substantial long-term value. SK Capital utilizes its industry, operating and investment experience to identify opportunities to transform businesses into higher performing organizations with improved strategic positioning, growth and profitability as well as lower operating risk. For more information, please visit www.skcapitalpartners.com.